SEC Tracker
Get the app

Rapport Therapeutics RAPP

Rapp Therapeutics offers $150M convertible notes due 2032

Securities offering

Form
424B5
Filed
Importance
Routine
  1. $150,000,000 principal amount of 2.25% convertible notes due 2032
  2. Conversion rate of 37.3483 shares per $1,000 principal
  3. Redemption possible after Dec 6, 2030, if stock price is 130% of conversion price
  4. Concurrent private placement of 1,428,571 shares at $21 per share

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Rapport Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  2. Ocugen OCGN public float $279M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025